Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOMENICA: Dostarlimab vs Chemotherapy in MMR-deficient Advanced Endometrial Cancer
2021-002124-21Phase 3Active
- Sponsor
- Arcagy-Gineco
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of dostarlimab in endometrial cancer (EC) (2 arms), sponsored by Arcagy-Gineco. Primary endpoint: Progression-free survival. Started Oct 2021; status: active.
02
Drugs
dostarlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2021-002124-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002124-21.